The global preclinical antibacterial pipeline

  25 November 2019

This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history.

Source: Nature
Author(s): Ursula Theuretzbacher , Kevin Outterson, Aleks Engel & Anders Karlén
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
  • No costs (until year end 2019)

Festive Launch Database 19 Nov Symposium Dinner ‘Emerging Antimicrobials and Diagnostics in AMR 2019
Click to join the Symposium Dinner (to join the Symposium separate registration obligatory)

Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!